Table 1 Clinicopathological characteristics of the study population.

Patients enrolled

151

100

95

63

56

37

Age (median, range, Y)

67

26–89

67

31–89

66

26–83

0.132

Gender

0.466

 Male

90

60

54

57

36

64

 Female

61

40

41

43

20

36

Race

<0.001

 White Hispanic or Latino

70

46

18

20

52

95

 White not-Hispanic nor Latino

69

46

66

73

3

5

 Asian

1

1

1

1

0

0

 Black or African American

6

4

6

7

0

0

Tumor Location

0.046

 GE Junction/Cardia/Proximal

45

30

29

31

16

29

 Fundus/Body

60

40

32

34

28

50

 Antrum/Distal

42

28

33

35

9

16

Lauren’s classification

0.174

 Intestinal

88

58

59

62

29

53

 Diffuse

51

34

27

28

24

44

 Mixed

10

7

8

8

2

4

 Medullary

1

1

1

1

0

0

 Primary tumor (T)

<0.001

  1

2

1

2

2

0

0

  2

6

4

6

6

0

0

  3

47

31

41

43

6

11

  4

56

37

31

33

25

45

  x

40

26

15

16

25

45

 Regional lymph nodes (N)

<0.001

  0

9

6

8

8

1

2

  1

25

17

20

21

5

9

  2

28

19

26

27

2

4

  3

25

17

15

16

10

18

  x

64

42

26

27

38

68

 Distant metastasis (M)

0.086

  0

55

36

40

42

15

27

  1

96

64

55

58

41

73

Molecular characterisation

0.028

 MSI/EBV−

18

12

16

17

2

4

 MSS/EBV−

126

83

74

79

52

93

 MSS/EBV+

6

4

4

4

2

4

HER2 status

0.467

 Negative

136

90

83

90

53

95

 Positive

12

8

9

10

3

5

CPS score

0.002

 0–5%

52

34

22

23

30

54

 5–10%

14

9

11

12

3

5

 >10%

76

50

54

57

22

39

 CD3

3797

37–20,083

4104

473–20,083

3289

37–9103

0.124

 CD8

2718

17–23,563

2874

17–23,563

2453

107–8593

0.382

 FOXP3

556

35–2820

616

35–2820

457

35–1440

0.056